DGS3, DSC3, PKP1, EVPL, IVL, FLG, SPRR1A and SPRR1B may be considered as new biomarkers in the therapeutics of metastatic melanoma, which might help us predict the potential metastatic capability of SKCM patients, thus provide earlier precautionary treatments. Here, PKP1 is linked to metastatic melanoma.